These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

507 related items for PubMed ID: 11588952

  • 1. [Effectiveness of chemotherapy of intrathoracic tuberculosis in children: late follow-up data].
    Iukhimenko NV.
    Probl Tuberk; 2001; (5):19-22. PubMed ID: 11588952
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [Contemporary methods in the diagnosis and treatment of intrathoracic tuberculosis in children].
    Mitinskaia LA, Elufimova VF, Iukhimenko NV, Pogodaeva NP, Iavorskiĭ KM.
    Probl Tuberk; 1994; (6):16-8. PubMed ID: 7708637
    [Abstract] [Full Text] [Related]

  • 4. Rifapentine and isoniazid in the continuation phase of a 6-month regimen. Final report at 5 years: prognostic value of various measures.
    Tam CM, Chan SL, Kam KM, Goodall RL, Mitchison DA.
    Int J Tuberc Lung Dis; 2002 Jan; 6(1):3-10. PubMed ID: 11931398
    [Abstract] [Full Text] [Related]

  • 5. [Optimization of chemotherapy regimens in children with primary pulmonary tuberculosis].
    Ovchinnikova IuE, Starshinova AA, Dovgaliuk IF.
    Probl Tuberk Bolezn Legk; 2009 Jan; (1):36-40. PubMed ID: 19256011
    [Abstract] [Full Text] [Related]

  • 6. Results of a 12-month regimen for drug-resistant pulmonary tuberculosis.
    Pérez-Guzmán C, Vargas MH, Martínez-Rossier LA, Torres-Cruz A, Villarreal-Velarde H.
    Int J Tuberc Lung Dis; 2002 Dec; 6(12):1102-9. PubMed ID: 12546119
    [Abstract] [Full Text] [Related]

  • 7. Treatment of isoniazid-resistant tuberculosis with isoniazid, rifampin, ethambutol, and pyrazinamide for 6 months.
    Nolan CM, Goldberg SV.
    Int J Tuberc Lung Dis; 2002 Nov; 6(11):952-8. PubMed ID: 12475140
    [Abstract] [Full Text] [Related]

  • 8. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
    Saito W, Nagayama N, Miyamoto M, Hara H, Suzuki J, Masuda K, Baba M, Tamura A, Nagai H, Akagawa S, Kawabe Y, Machida K, Kurashima A, Yotsumoto H.
    Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
    [Abstract] [Full Text] [Related]

  • 9. Modified short-course chemotherapy of pulmonary tuberculosis in Ibadan, Nigeria--a preliminary report.
    Ige OM, Bakare NA, Onadeko BO.
    Afr J Med Med Sci; 2000 Mar; 29(1):51-3. PubMed ID: 11379469
    [Abstract] [Full Text] [Related]

  • 10. A controlled trial of 6 months' chemotherapy in pulmonary tuberculosis. Final report: results during the 36 months after the end of chemotherapy and beyond. British Thoracic Society.
    Br J Dis Chest; 1984 Oct; 78(4):330-6. PubMed ID: 6386028
    [Abstract] [Full Text] [Related]

  • 11. Long-term follow-up of a clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. Singapore Tuberculosis Service/British Medical Research Council.
    Am Rev Respir Dis; 1986 May; 133(5):779-83. PubMed ID: 2871788
    [Abstract] [Full Text] [Related]

  • 12. [Estimation of the possibilities of using unified chemotherapy regimens in new cases of pulmonary tuberculosis in old-age children and adolescents].
    Gubkina MF, Ershova NG.
    Probl Tuberk Bolezn Legk; 2009 May; (1):33-6. PubMed ID: 19256010
    [Abstract] [Full Text] [Related]

  • 13. Study of drug resistance in previously treated tuberculosis patients in Gujarat, India.
    Shah AR, Agarwal SK, Shah KV.
    Int J Tuberc Lung Dis; 2002 Dec; 6(12):1098-101. PubMed ID: 12546118
    [Abstract] [Full Text] [Related]

  • 14. [Experimental evidence for Mycobacterium tuberculosis persistence in M. tuberculosis-infected H37RV mice in the treatment with 3 first-line drugs (rifampicin, isoniazid, pyrazinamide)].
    Smirnova TG, Chernousova LN, Andreevskaia SN, Nikolaeva GM.
    Probl Tuberk Bolezn Legk; 2004 Dec; (3):32-7. PubMed ID: 15338898
    [Abstract] [Full Text] [Related]

  • 15. A comparison of two short course tuberculosis chemotherapy regimens, both using Rifater during an intensive phase, with a 3 year follow-up.
    Punnotok J, Pumprueg U, Chakorn T.
    J Med Assoc Thai; 1995 Jun; 78(6):298-304. PubMed ID: 7561554
    [Abstract] [Full Text] [Related]

  • 16. [Efficiency of an intensive stage of chemotherapy for tuberculosis in elderly and senile patients].
    Karachunskiĭ MA, Uvarova TE.
    Probl Tuberk Bolezn Legk; 2004 Jun; (3):19-21. PubMed ID: 15338894
    [Abstract] [Full Text] [Related]

  • 17. Is the combination of pyrazinamide plus rifampicin safe for treating latent tuberculosis infection in persons not infected by the human immunodeficiency virus?
    Tortajada C, Martínez-Lacasa J, Sánchez F, Jiménez-Fuentes A, De Souza ML, García JF, Martínez JA, Caylà JA, Tuberculosis Prevention Working Group.
    Int J Tuberc Lung Dis; 2005 Mar; 9(3):276-81. PubMed ID: 15786890
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Principles in the performance of chemotherapy in dispensary group VI children and adolescents].
    Ovsiankina ES, Gubkina MF, Kuz'mina IK, Stakheeva LB, Borodina NN, Zaletina EIu.
    Probl Tuberk Bolezn Legk; 2007 Mar; (8):25-8. PubMed ID: 17915463
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.